Lyme disease: A turning point

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 5, 2007, Pages 759-762

  Stricker, Raphael B ^a   Johnson, Lorraine ^a  

^a International Lyme and Associated Diseases Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; DOXYCYCLINE; PLACEBO;

ANTIBIOTIC THERAPY; BORRELIA BURGDORFERI; CLINICAL TRIAL; COGNITION; COMORBIDITY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; EDITORIAL; FATIGUE; HUMAN; LABORATORY DIAGNOSIS; LYME DISEASE; MEDICAL SOCIETY; OUTCOMES RESEARCH; PHYSICAL PERFORMANCE; PRACTICE GUIDELINE; QUALITY OF LIFE; SHORT COURSE THERAPY; TICK BORNE DISEASE;

EID: 35348977184     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.5.759     Document Type: Editorial

References (29)

1. Stricker RB, Lautin A, Burrascano JJ. Lyme disease: point/counterpoint. Expert Rev. Anti Infect. Ther. 3, 155-165 (2005).
2. Harvey WT, Salvato P. 'Lyme disease': ancient engine of an unrecognized borreliosis pandemic? Med. Hypotheses 60, 742-759 (2003).
3. Wormser GP, Dattwyler RJ, Shapiro ED et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 41, 1089-1134 (2006).
4. Cameron D, Gaito A, Harris N et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev. Anti Infect. Ther. 2(1 Suppl.), S1-S13 (2004).
5. Phillips SE, Harris NS, Horowitz R, Johnson L, Stricker RB. Lyme disease: scratching the surface. Lancet 366, 1771 (2005).
6. Phillips SE, Burrascano JJ, Harris NS, Johnson L, Smith PV, Stricker RB. Chronic infection in 'post-Lyme borreliosis syndrome'. Int. J Epidemiol. 34, 1439-1440 (2005).
7. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 48, 534-540 (2003).
8. Kalish RS, Wood JA, Golde W et al. Human T lymphocyte response to Borrelia burgdorferi infection: no correlation between human leukocyte function antigen type 1 peptide response and clinical status. J. Infect. Dis. 187, 102-108 (2003).
9. Casjens S, Palmer N, van Vugt R et al. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol. Microbiol. 35, 490-516 (2000).
10. Embers ME, Ramamoorthy R, Philipp MT. Survival strategies of Borrelia burgdorferi the etiologic agent of Lyme disease. Microbes Infect. 6, 312-318 (2004).
11. Johnson L, Stricker RB. Treatment of Lyme disease: a medicolegal assessment. Expert Rev. Anti Infect. Ther. 2, 533-557 (2004).
12. Yrjänäinen H, Hytönen J, Song XY, Oksi J, Hartiala K, Viljanen MK. Anti-tumor necrosis factor-α treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. J. Infect. Dis. 195, 1489-1496 (2007).
13. Steinbrook R. Guidance for guidelines. N. Engl. J. Med. 356, 331-333 (2007).
14. Klempner MS, Hu LT, Evans J et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345, 85-92 (2001).
15. Lorber B. Update in infectious diseases. Ann. Intern. Med. 137, 974-980 (2002.)
16. Radolf J. Posttreatment chronic Lyme disease - what it is not. J. Infect. Dis. 192, 948-949 (2005).
17. Cameron DJ. Generalizability in two clinical trials of Lyme disease. Epidemiol. Perspect. Innov. 3, 12-18 (2006).
18. Krupp LB, Hyman LG, Grimson R et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60, 1923-1930 (2003).
19. Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Stapbylococcus aureus. South. Med. J. 98, 590-595 (2005).
20. Fallon BA, Keilp JG, Corbera KM et al. A randomized, placebo-controlled trial of repeated intfavenous antibiotic therapy for Lyme encephalopathy. Neurology (In press).
21. Keilp JG, Corbera K, Slavov I, Taylor MJ, Sackeim HA, Fallon BA. WAIS-III and WMS-III performance in chronic Lyme disease. J. Int. Neuropsychol. Soc. 12, 119-129 (2006).
22. Cameron DJ. Results from Lyme disease treatment trial. Presented at: Columbia University/LDA Conference, Lyme and Other Tick-Borne Diseases: Emerging Tick-Borne Diseases. Philadelphia, PA, USA, October 28, 2005.
23. Cameron DJ. Consequences of treatment delay in Lyme disease. J. Eval. Clin. Practice 13, 470-472 (2007).
24. Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin. Infect. Dis. 45, 149-157 (2007).
25. Von Lackum K, Babb K, Riley SP, Wattier RL, Bykowski T, Stevenson B. Functionality of Borrelia burgdorferi LuxS: the Lyme disease spirochete produces and responds to the pheromone autoinducer-2 and lacks a complete activated-methyl cycle. Int. J. Med. Microbiol. 296(Suppl. 40), 92-102 (2006).
26. Bulut Y, Faure E, Thomas L, Equils O, Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Bornelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J. Immunol. 167, 987-994 (2001).
27. Lella RK, Sharma C. EIS (enhanced intracellular survival) protein of Myrobacterium tuberculosis disturbs the cross regulation of T-cells. J. Biol. Chem. 282, 18671-18675 (2007).
28. Salazar JC, Pope CD, Moore MW, Pope J, Kiely TG, Radolf JD. Lipoprotein-dependent and -independent immune responses to spirochetal infection. Clin. Diagn. Lab. Immunol. 12, 949-958 (2005).
29. Ghigo E, Capo C, Raoult D, Mege JL. Interleukin-10 stimulates Coxiella burnetti replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever. Infect. Immun. 69, 2345-2352 (2001).